参丹散结胶囊辅助艾立布林治疗Her2阴性乳腺癌对免疫功能的影响  

Shendan Sanjie Capsules as An Adjunct to Eribulin in the Treatment of Her2 Negative Breast Cancer and Its Effect on Immune Function

作　　者：叶华斌 肖威 刘吉梅 王刚 叶颖 唐金绍 YE Huabin;XIAO Wei;LIU Jimei;WANG Gang;YE Ying;TANG Jinshao(Thoracic Surgery Department of Ganzhou Cancer Hospital,Ganzhou 341000,China;不详)

机构地区：[1]赣州市肿瘤医院胸外科,江西赣州341000

出　　处：《中国医学创新》2024年第30期1-6,共6页Medical Innovation of China

基　　金：2023年赣州市指导性科技计划项目(2023DXNS4193)。

摘　　要：目的:研究参丹散结胶囊辅助艾立布林治疗Her2阴性乳腺癌对免疫功能的影响。方法:选取2022年9月—2023年9月赣州市肿瘤医院收治的60例Her2阴性晚期乳腺癌患者为对象,随机分为观察组和对照组,各30例。对照组以艾立布林治疗,观察组以此增加参丹散结胶囊治疗。评估两组临床疗效、肿瘤标志物水平、免疫功能、生物标记蛋白、炎症因子、安全性等。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组肿瘤标志物糖类抗原153(CA153)、癌胚抗原(CEA)、糖类抗原125(CA125)水平均低于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于对照组,CD8^(+)低于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组Foxa2、p27kip1均高于对照组,增殖细胞核抗原(PCNA)低于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组炎症细胞因子中的肿瘤坏死因子-α(TNF-α)、可溶性白细胞介素-2受体(sIL-2R)、白细胞介素-12(IL-12)、白细胞介素-6(IL-6)水平均低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:参丹散结胶囊联合艾立布林治疗Her2阴性晚期乳腺癌效果较好,抑制肿瘤标志物表达,改善免疫功能和乳腺癌相关生物标记蛋白,降低炎症因子水平,安全性良好。Objective:To study the effect of Shendan Sanjie Capsules on immune function in the treatment of Her2 negative breast cancer with Eribulin.Method:A total of 60 cases of Her2 negative advanced breast cancer patients admitted to Ganzhou Cancer Hospital from September 2022 to September 2023 were selected and randomly divided into observation group and control group,with 30 cases each.The control group was treated with Eribulin,and the observation group was treated with this addition of Shendan Sanjie Capsules.The clinical efficacy,tumor marker levels,immune function,biomarker proteins,inflammatory factors,safety,etc.of two groups were evaluated.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)in observation group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and CD8^(+)was lower than that in the control group,with statistical significance(P<0.05).After treatment,Foxa2 and p27kip1 in the observation group were higher than those in the control group,and proliferating cell nuclear antigen(PCNA)was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of inflammatory cytokines tumor necrosis factor-α(TNF-α),soluble interleukin-2 receptor(sIL-2R),interleukin-12(IL-12)and interleukin-6(IL-6)in observation group were lower than those in control group,with statistical significance(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Shendan Sanjie Capsules combined with Eribulin has better efficacy in the treatment of Her2 negative advanced breast cancer,inhibits the expression of tumor markers,improv

关 键 词：乳腺癌 艾立布林 参丹散结胶囊 治疗安全性 免疫功能 生活质量 

分 类 号：R737.9[医药卫生—肿瘤]